SciClone Pharma Gains CFDA Approval for Liver Cancer Treatment

SciClone Pharma, a California company that in-licenses drug products for the China market, received CFDA approval for DC Bead®, a minimally invasive treatment for liver cancer made by BTG plc of the UK. SciClone has exclusive China distribution rights to DC Bead, which it will purchase from BTG at an agreed-upon price. SciClone's current major product is Zadaxin®, a treatment for the liver diseases hepatitis B and C. More details.... Stock Symbols: (NSDQ: SCLN) (LSE: BTG) Share this with colleagues: // //